Gilmartin Capital is a venture capital firm focused on private investments in the medical device, life science tools, diagnostic, and digital health sectors. The firm backs entrepreneurs targeting platforms that influence large or underserved diseases and technologies that accelerate scientific discovery, investing in opportunities beyond proof of concept poised for significant development and growth.
60% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $106.4M (across 8 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series E
Last 12 Mo
2
Team
Jonathan Demchick
Co-Founder & Principal
David Lewis
Managing Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
 Galvanize | Bridge | — | Sep 2025 |
 Shoulder Innovations | Series E | $40M | Mar 2025 |
| Shoulder Innovations | Series E | $40M | Jan 2025 |
 INSIGHTEC | Growth | $150M | Jun 2024 |
 Kestra Medical Technologies | Unknown | $196M | Jan 2024 |
| Galvanize Therapeutics | Series B | $100M | Sep 2022 |
| Kestra Medical Technologies | Bridge | — | — |
| AAlleviant Medical, Inc. | Unknown | $75M | — |
 Insightec | Growth | $150M | — |
Top Co-Investors
Ally Bridge Group6 shared
Fidelity Investments3 shared
Apple Tree Partners3 shared
Perceptive Advisors3 shared
T. Rowe Price2 shared
Elevage Medical Technologies2 shared
Intuitive Surgical2 shared
Sofinnova Partners2 shared
Intuitive Ventures2 shared
Norwest Venture Partners2 shared
U.S. Venture Partners2 shared
Aperture Venture Partners2 shared
Gilde Healthcare2 shared
Sectoral Asset Management2 shared
Nexus NeuroTech Ventures2 shared
Catalio Capital Management2 shared
Baillie Gifford2 shared
Andera Partners2 shared
Last updated: 7 October 2026